资金流向方面，今日主力资金净流出3226.26万元，占比成交额10.38%。其中，超大单净流出3200.80万 元、占成交额10.3%，大单净流出25.46万元、占成交额0.08%，中单净流出流入523.46万元、占成交额 1.68%，小单净流入2702.79万元、占成交额8.7%。 通过天眼查大数据分析，山东新华医疗器械股份有限公司共对外投资了54家企业，参与招投标项目5000 次，知识产权方面有商标信息103条，专利信息4360条，此外企业还拥有行政许可347个。 来源：金融界 新华医疗最新一期业绩显示，截至2025一季报，公司营业总收入23.08亿元、同比减少8.74%，归属净利 润1.60亿元，同比减少23.97%，扣非净利润1.58亿元，同比减少24.53%，流动比率1.323、速动比率 0.837、资产负债率46.69%。 天眼查商业履历信息显示，山东新华医疗器械股份有限公司，成立于1993年，位于淄博市，是一家以从 事专用设备制造业为主的企业。企业注册资本60667.7919万人民币，实缴资本17538.5227万人民币。公 司法定代表人为王玉全。 金融界消息 截至2025年8月14日收盘，新华 ...

Core Viewpoint - The article highlights the transformation and innovation within Shandong's manufacturing sector, particularly focusing on the advancements made by Xinhua Surgical Instruments Co., a subsidiary of Shandong Xinhua Medical Instruments Co., in the production of surgical instruments through automation and smart manufacturing technologies [1][3]. Group 1: Company Overview - Xinhua Surgical Instruments has evolved over 80 years, expanding from basic surgical tools to a diverse product line that includes over 14,000 varieties of surgical instruments, equipment, and consumables, establishing itself as a leading enterprise in the industry [3][4]. - The company has achieved significant milestones in product development, with a focus on high-quality surgical instruments that meet stringent material and craftsmanship standards [4][5]. Group 2: Technological Advancements - The implementation of intelligent manufacturing systems has reduced labor intensity by 30% and improved production efficiency, showcasing a shift from manual labor to automated processes [3][4]. - The company has integrated advanced technologies such as robotic vision systems into its production lines, enhancing safety and efficiency in manufacturing [3][4]. Group 3: Market Expansion - Xinhua Surgical Instruments has successfully penetrated international markets, with its products being sold in Europe, America, Japan, South Korea, and several countries along the Belt and Road Initiative [4]. - The company has introduced a comprehensive management solution for surgical instruments, aimed at extending the lifespan of the instruments and minimizing medical risks for clients [4].

Company Overview - Shandong Xinhua Medical Equipment Co., Ltd. specializes in the manufacturing and sales of medical devices and pharmaceutical equipment, providing compatible medical services and medical commerce [2] - The company is a leading entity in the Chinese medical device industry, holding several key positions in various associations and has developed innovative products such as the world's first peracetic acid low-temperature sterilizer [2] Financial Performance - For Q1 2025, the company reported revenue of 2.308 billion yuan, a year-on-year decrease of 8.74%, and a net profit of 160 million yuan, down 23.97% compared to the previous year [3] - The company's gross profit margin stood at 23.79% [3] Market Position - As of August 11, the company's stock closed at 18.14 yuan, with a rolling price-to-earnings (PE) ratio of 17.17, marking a new low in 161 days [1] - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Xinhua Medical at the 36th position within the industry [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xinhua Medical reached 38,959, an increase of 5,308 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

天眼查商业履历信息显示，山东新华医疗器械股份有限公司，成立于1993年，位于淄博市，是一家以从 事专用设备制造业为主的企业。企业注册资本60667.7919万人民币，实缴资本17538.5227万人民币。公 司法定代表人为王玉全。 通过天眼查大数据分析，山东新华医疗器械股份有限公司共对外投资了54家企业，参与招投标项目5000 次，知识产权方面有商标信息103条，专利信息4357条，此外企业还拥有行政许可347个。 来源：金融界 金融界消息 截至2025年8月11日收盘，新华医疗（600587）报收于18.14元，上涨4.43%，换手率 6.26%，成交量37.86万手，成交金额6.91亿元。 资金流向方面，今日主力资金净流入2682.44万元，占比成交额3.88%。其中，超大单净流入4174.63万 元、占成交额6.04%，大单净流出1492.19万元、占成交额2.16%，中单净流出流出4309.95万元、占成交 额6.24%，小单净流入1627.52万元、占成交额2.36%。 新华医疗最新一期业绩显示，截至2025一季报，公司营业总收入23.08亿元、同比减少8.74%，归属净利 润1.60亿元，同比减少 ...

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...

证券之星消息，8月8日山东国企改革板块较上一交易日下跌0.08%，东杰智能领跌。当日上证指数报收 于3635.13，下跌0.12%。深证成指报收于11128.67，下跌0.26%。山东国企改革板块个股涨跌见下表： 从资金流向上来看，当日山东国企改革板块主力资金净流出7.03亿元，游资资金净流入1.42亿元，散户资 金净流入5.61亿元。山东国企改革板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000803 | 山高环能 | 7.32 | 7.02% | 40.76万 | 2.92亿 | | 000811 | 冰轮环境 | 13.34 | 5.54% | 79.00万 | 10.34亿 | | 000756 | 新华制药 | 16.83 | 2.62% | 22.54万 | 3.76亿 | | 603318 | 水发燃气 | 7.01 | 2.34% | 18.25万 | 1.28亿 | | 600587 | 新华医疗 | 17.37 | 1.94% | 19.36万 ...

天眼查商业履历信息显示，山东新华医疗器械股份有限公司，成立于1993年，位于淄博市，是一家以从 事专用设备制造业为主的企业。企业注册资本60667.7919万人民币，实缴资本17538.5227万人民币。公 司法定代表人为王玉全。 通过天眼查大数据分析，山东新华医疗器械股份有限公司共对外投资了54家企业，参与招投标项目5000 次，知识产权方面有商标信息103条，专利信息4356条，此外企业还拥有行政许可347个。 来源：金融界 金融界消息 截至2025年8月7日收盘，新华医疗（600587）报收于17.04元，下跌0.7%，换手率2.87%， 成交量17.34万手，成交金额2.97亿元。 资金流向方面，今日主力资金净流入2119.97万元，占比成交额7.13%。其中，超大单净流入602.79万 元、占成交额2.03%，大单净流入1517.18万元、占成交额5.11%，中单净流出流入542.67万元、占成交 额1.83%，小单净流出2662.64万元、占成交额8.96%。 新华医疗最新一期业绩显示，截至2025一季报，公司营业总收入23.08亿元、同比减少8.74%，归属净利 润1.60亿元，同比减少23.9 ...

Core Viewpoint - As of August 6, 2025, Xinhua Medical (600587) closed at 17.16 yuan, reflecting a 1.3% increase, with a trading volume of 240,400 hands and a transaction value of 408 million yuan [1] Group 1: Financial Performance - For Q1 2025, Xinhua Medical reported a main revenue of 2.308 billion yuan, a year-on-year decrease of 8.74% [3] - The net profit attributable to shareholders was 160 million yuan, down 23.97% year-on-year [3] - The company’s gross profit margin stood at 23.79%, significantly lower than the industry average of 51.31% [3] Group 2: Market Activity - On August 6, 2025, the net outflow of main funds was 24.2252 million yuan, accounting for 5.93% of the total transaction value [1][2] - Retail investors experienced a net outflow of 1.2066 million yuan, representing 0.3% of the total transaction value [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with notable net inflows from speculative funds on August 6 [2] Group 3: Company Metrics and Industry Comparison - Xinhua Medical's total market capitalization is 10.411 billion yuan, ranking 35th in the medical device industry [3] - The company has a price-to-earnings ratio of 16.22, significantly lower than the industry average of 61.65, ranking 4th in the industry [3] - The return on equity (ROE) for Xinhua Medical is 2.09%, which is higher than the industry average of 1.09%, ranking 40th [3] Group 4: Analyst Ratings - In the last 90 days, four institutions have rated the stock, with two buy ratings and two hold ratings [4] - The average target price set by institutions over the past 90 days is 22.27 yuan [4]

来源：金融界 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，新华医疗排 名第33位。 股东方面，截至2025年3月31日，新华医疗股东户数38959户，较上次增加5308户，户均持股市值35.28 万元，户均持股数量2.76万股。 山东新华医疗器械股份有限公司的主营业务是医疗器械、制药装备的制造销售，提供适配的医疗服务与 医疗商贸。公司的主要产品是医疗器械制造产品、制药装备产品、医疗商贸产品、医疗服务。公司是中 国医疗器械行业协会会长单位，中国医学装备协会副理事长单位，感染与控制技术专业委员会理事长单 位，中国放射治疗产业技术创新战略联盟理事长单位，中国制药装备行业协会理事单位，中国医药设备 工程协会理事单位。公司研制开发了全球第一台过氧乙酸低温灭菌器、国内首台高能医用电子直线加速 器等高精尖产品，建成了国内首个智慧化消毒供应中心等行业创新工程，荣获了中国灭菌设备领域第一 张FDA认证证书。公司是国家重点高新技术企业，拥有行业内第一家国家认定企业技术中心，设有"博 士后科研工作站"、"先进医疗设备及器械山东省工程研究中心"等多个省级技术研发平台，每年新增重 点技术创 ...

7月31日，新华医疗今日收盘16.61元，下跌1.19%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到15.72倍，总市值100.77亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入23.08亿元，同比-8.74%；净利润1.60亿元，同 比-23.97%，销售毛利率23.79%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)3新华医疗15.7214.571.28100.77亿行业平均 54.8949.974.71114.46亿行业中值37.0636.862.6754.89亿1九安医疗10.9311.060.86184.50亿2英科医疗 14.2315.351.27224.88亿4山东药玻15.9516.001.83150.91亿5奥美医疗16.2315.911.6758.64亿6振德医疗 16.2415.301.0358.94亿7康德莱17.1117.121.4236.87亿8九强生物17.3416.132.1285.89亿9维力医疗 17.4318.622.1940.86亿10奥泰生物17.8318.801.4456.86亿11鱼跃医疗19.7419.362.6734 ...